Investments
15Portfolio Exits
12Partners & Customers
10About Teva Pharmaceuticals
Teva Pharmaceutical Industries, headquartered in Israel, is a generic pharmaceutical company. Teva develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients.

Want to inform investors similar to Teva Pharmaceuticals about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Teva Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Teva Pharmaceuticals in 3 Expert Collections, including Conference Exhibitors.
Conference Exhibitors
5,302 items
Medical Devices
295 items
Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA
Biopharma Tech
260 items
Research containing Teva Pharmaceuticals
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Teva Pharmaceuticals in 2 CB Insights research briefs, most recently on Apr 19, 2021.


Dec 17, 2020
5 Ways Digital Twins Could Improve HealthcareLatest Teva Pharmaceuticals News
Jan 27, 2023
Teva Pharmaceuticals Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global substance abuse treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global substance abuse treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global substance abuse treatment market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report. Thus, the research study provides a holistic view of the global substance abuse treatment market, offering market size and estimates for the period from 2020 to 2030, keeping in mind the above-mentioned factors. Substance abuse is a compulsive, excessive, and self-damaging use of habit forming drugs or substances; leading to addiction, dependence, serious physiological injury, psychological harm or death. Factors such as alarming rise in the number of substance addicted population, rise in the number of opioid prescriptions written by physicians, increased government intervention and encouragement to curb substance abuse in all countries are driving the growth of substance abuse treatment market globally. However, low treatment compliance may negatively impact the growth of market. In the base year 2016, drug abuse treatment held largest market share due to the factors such as higher alarming rise in the number of drug addicted population, increased government intervention and encouragement to curb substance abuse and rise in the number of opioid prescriptions written by physicians are driving the growth of drug abuse treatment market globally. In the base year 2020, North America dominated the substance abuse treatment market in terms of revenue and it is anticipated that it will show significant growth during the forecast period; U.S. was observed as largest regional market in North America. Factors such as alarming rise in the number of addicted population, government initiatives in substance abuse prevention and treatment, high awareness about the threats to life and economic burden, and evolved government policies for the same are the prime contributors to the dominance of North America. Expenditure on healthcare is highest in the U.S. as compared to other nations. It is anticipated that Asia Pacific will grow at highest CAGR during the forecast period due to developing economic condition, improvement in awareness among general patient population, improved treatment access, growing addiction rates along with rise in awareness and evolution of healthcare infrastructure would fuel the growth during the forecast period. Historical & Forecast Period This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030. Key questions answered in this report What are the key micro and macro environmental factors that are impacting the growth of Substance Abuse Treatment market? What are the key investment pockets with respect to product segments and geographies currently and during the forecast period? Estimated forecast and market projections up to 2030. Which segment accounts for the fastest CAGR during the forecast period? Which market segment holds a larger market share and why? Are low and middle-income economies investing in the Substance Abuse Treatment market? Which is the largest regional market for Substance Abuse Treatment market? What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa? Which are the key trends driving Substance Abuse Treatment market growth? Who are the key competitors and what are their key strategies to enhance their market presence in the Substance Abuse Treatment market worldwide? For more information about this report visit https://www.researchandmarkets.com/r/tdw1wq-abuse?w=4 Contacts
Teva Pharmaceuticals Investments
15 Investments
Teva Pharmaceuticals has made 15 investments. Their latest investment was in Remedix as part of their Corporate Minority - II on September 9, 2019.

Teva Pharmaceuticals Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
9/9/2019 | Corporate Minority - II | Remedix | Yes | 1 | ||
5/18/2017 | Corporate Minority | Heptares Therapeutics | $5M | Yes | 2 | |
6/18/2015 | Corporate Minority - II | Keratin Biosciences | $35M | Yes | 1 | |
6/2/2015 | Corporate Minority | |||||
5/15/2012 | Series E |
Date | 9/9/2019 | 5/18/2017 | 6/18/2015 | 6/2/2015 | 5/15/2012 |
---|---|---|---|---|---|
Round | Corporate Minority - II | Corporate Minority | Corporate Minority - II | Corporate Minority | Series E |
Company | Remedix | Heptares Therapeutics | Keratin Biosciences | ||
Amount | $5M | $35M | |||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 2 | 1 |
Teva Pharmaceuticals Portfolio Exits
12 Portfolio Exits
Teva Pharmaceuticals has 12 portfolio exits. Their latest portfolio exit was Immuneering on July 30, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
7/30/2021 | IPO | Public | 6 | ||
9/17/2020 | IPO | Public | 11 | ||
10/26/2018 | IPO | Public | 4 | ||
Date | 7/30/2021 | 9/17/2020 | 10/26/2018 | ||
---|---|---|---|---|---|
Exit | IPO | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | Public | ||
Sources | 6 | 11 | 4 |
Teva Pharmaceuticals Acquisitions
15 Acquisitions
Teva Pharmaceuticals acquired 15 companies. Their latest acquisition was Allergan - Anda Distribution Business on August 05, 2016.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
8/5/2016 | Acquired Unit | 1 | ||||
8/2/2016 | Acquired Unit | 4 | ||||
7/27/2016 | Acquired Unit | 4 | ||||
10/1/2015 | ||||||
9/25/2015 |
Date | 8/5/2016 | 8/2/2016 | 7/27/2016 | 10/1/2015 | 9/25/2015 |
---|---|---|---|---|---|
Investment Stage | |||||
Companies | |||||
Valuation | |||||
Total Funding | |||||
Note | Acquired Unit | Acquired Unit | Acquired Unit | ||
Sources | 1 | 4 | 4 |
Teva Pharmaceuticals Partners & Customers
10 Partners and customers
Teva Pharmaceuticals has 10 strategic partners and customers. Teva Pharmaceuticals recently partnered with HealthSnap on November 11, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
11/14/2022 | Partner | United States | HealthSnap is continuously seeking partnerships and we look forward to delivering quality at home programs with this new and exciting collaboration with Teva Pharmaceuticals , '' said Samson Magid , Co-Founder and CEO of HealthSnap . | 3 | |
11/14/2022 | Partner | United States | Teva, Rimidi team up to integrate respiratory digital health data Teva said its U.S. affiliate is collaborating with clinical management platform Rimidi to expand the reach of its respiratory digital health platform . | 5 | |
10/25/2022 | Partner | United States | Community Routes : Access to Mental Healthcare , a partnership between Direct Relief , the National Association of Free and Charitable Clinics , and Teva Pharmaceuticals , provides awards to support clinics expanding access to mental health services across three states . | 2 | |
10/18/2022 | Partner | ||||
10/18/2022 | Partner |
Date | 11/14/2022 | 11/14/2022 | 10/25/2022 | 10/18/2022 | 10/18/2022 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | United States | United States | United States | ||
News Snippet | HealthSnap is continuously seeking partnerships and we look forward to delivering quality at home programs with this new and exciting collaboration with Teva Pharmaceuticals , '' said Samson Magid , Co-Founder and CEO of HealthSnap . | Teva, Rimidi team up to integrate respiratory digital health data Teva said its U.S. affiliate is collaborating with clinical management platform Rimidi to expand the reach of its respiratory digital health platform . | Community Routes : Access to Mental Healthcare , a partnership between Direct Relief , the National Association of Free and Charitable Clinics , and Teva Pharmaceuticals , provides awards to support clinics expanding access to mental health services across three states . | ||
Sources | 3 | 5 | 2 |
Teva Pharmaceuticals Team
69 Team Members
Teva Pharmaceuticals has 69 team members, including current President, Mike Netz.
Name | Work History | Title | Status |
---|---|---|---|
Mike Netz | President | Current | |
Name | Mike Netz | ||||
---|---|---|---|---|---|
Work History | |||||
Title | President | ||||
Status | Current |
Compare Teva Pharmaceuticals to Competitors
BRAVIS is a software and system house. It develops high-end internet-based video conference systems.

Pfizer (NYSE: PFE) offers a diversified health care portfolio including human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer products. It works across various markets to promote wellness, prevention, treatments, and cures that challenge feared diseases. The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. The company was founded in 1849 and is based in New York, New York.

FoodMarble has developed a personal digestive tracker. Based on validated clinical technology, this tiny breath test device and app can be used with the help of AI to help people work out what foods are most compatible with their unique digestive system.

Civica Rx is a not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving generic medications.

Syntr Health Technologies specializes in the micro fragmentation of adipose tissue for body contouring. The company was founded in 2016 and is based in Irvine, California.
HAPLN Science is a drug development company that focuses on anti-aging therapies that can reverse tissue and organ degeneration. The company's products include treatments for degenerative arthritis, skin aging treatment, hair loss, and connective tissue disease. HAPLN Science was founded in 2018 and is based in Seongnam, South Korea.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.